Skip to main content
High RiskFDAfda-F-1591-2018OTHER

Blood & Internal Cleanser, Dietary Supplement

Category
Units Affected
60
Recall Date
May 20, 2018
Issuing Agency
Hazard
Other

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1591-2018.

The product Blood & Internal Cleanser is a dietary supplement with drug claims and iron content at 67 & 69% of declared, per laboratory results. The product Belly Fat Reducer + Energy Booster and Stamina declares incorrect amount of Vitamin B6. The product label declares 50mg and only contains 0.1 mg as per laboratory results.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1591-2018.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Nutreglo Products, Llc. or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1591-2018.

Nutreglo Products, LLC.

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Nutreglo Products, Llc. Recall FAQ

Nutreglo Products, Llc. is the subject of a supplements safety report: Blood & Internal Cleanser, Dietary Supplement. The notice was published on May 20, 2018 by the U.S. Food and Drug Administration (FDA). Approximately 60 units are potentially affected.